IRIS - Res&Arch Institutional Research Information System - Research & Archive

GAETANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.711
AS - Asia 2.163
EU - Europa 1.463
SA - Sud America 328
Continente sconosciuto - Info sul continente non disponibili 150
AF - Africa 65
OC - Oceania 8
Totale 6.888
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.625
SG - Singapore 1.011
IT - Italia 364
CN - Cina 314
HK - Hong Kong 279
BR - Brasile 246
IE - Irlanda 223
RU - Federazione Russa 209
VN - Vietnam 139
DE - Germania 127
FR - Francia 99
BD - Bangladesh 98
KR - Corea 76
SE - Svezia 75
FI - Finlandia 71
GB - Regno Unito 62
IN - India 54
CA - Canada 45
NL - Olanda 38
JP - Giappone 28
RO - Romania 28
TR - Turchia 27
AR - Argentina 25
UA - Ucraina 23
PL - Polonia 22
IQ - Iraq 21
ZA - Sudafrica 20
AT - Austria 19
BE - Belgio 19
CZ - Repubblica Ceca 18
ID - Indonesia 17
UZ - Uzbekistan 15
CO - Colombia 14
MX - Messico 14
PK - Pakistan 14
SA - Arabia Saudita 13
VE - Venezuela 11
EC - Ecuador 10
ES - Italia 10
GR - Grecia 9
HR - Croazia 9
PH - Filippine 9
MA - Marocco 8
JM - Giamaica 7
NI - Nicaragua 7
PT - Portogallo 7
TN - Tunisia 7
CL - Cile 6
KZ - Kazakistan 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
LT - Lituania 5
NZ - Nuova Zelanda 5
AZ - Azerbaigian 4
CH - Svizzera 4
EG - Egitto 4
KE - Kenya 4
UY - Uruguay 4
BG - Bulgaria 3
DK - Danimarca 3
DZ - Algeria 3
ET - Etiopia 3
GE - Georgia 3
HN - Honduras 3
IR - Iran 3
JO - Giordania 3
KG - Kirghizistan 3
LB - Libano 3
MD - Moldavia 3
PA - Panama 3
SC - Seychelles 3
TW - Taiwan 3
AL - Albania 2
BB - Barbados 2
BO - Bolivia 2
GM - Gambi 2
GY - Guiana 2
IS - Islanda 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
SD - Sudan 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BY - Bielorussia 1
BZ - Belize 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
HT - Haiti 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 6.722
Salva come PNG Salva come JPEG
Città #
Singapore 749
San Jose 349
Hong Kong 268
Chandler 257
Ashburn 245
Dublin 222
Perugia 146
Boardman 123
Santa Clara 105
Los Angeles 91
Moscow 85
Beijing 78
Seoul 76
Lauterbourg 69
Munich 69
San Mateo 69
New York 62
Altamura 59
Des Moines 43
Medford 40
Princeton 40
Andover 39
Lawrence 39
Piscataway 39
Ann Arbor 38
Ho Chi Minh City 37
Hanoi 36
Wilmington 36
The Dalles 35
Helsinki 31
Turku 26
Redmond 24
São Paulo 23
Tokyo 23
Denver 22
Phoenix 22
Boston 21
Chennai 21
Rome 21
Brooklyn 20
Houston 20
Amsterdam 19
Dallas 19
Redwood City 18
Chicago 17
Montreal 17
Orem 17
Nuremberg 16
Buffalo 15
Frankfurt am Main 15
Stockholm 15
Brussels 14
Falls Church 14
Milan 14
Vienna 14
Warsaw 14
London 13
Atlanta 12
Brno 12
Johannesburg 12
Manchester 12
San Francisco 11
Seattle 11
Tashkent 11
Council Bluffs 10
Poplar 10
Rio de Janeiro 10
Timisoara 10
Haiphong 9
Columbus 8
Hefei 8
Zagreb 8
Baghdad 7
Fairfield 7
Florence 7
Lappeenranta 7
Managua 7
Belo Horizonte 6
Bucharest 6
Charlotte 6
Da Nang 6
Falkenstein 6
Guangzhou 6
Kingston 6
Lahore 6
Mexico City 6
New Delhi 6
Norwalk 6
Saint Petersburg 6
Secaucus 6
Toronto 6
Ankara 5
Auckland 5
Campinas 5
Dong Ket 5
Miami 5
Newark 5
Quito 5
Riyadh 5
Woodbridge 5
Totale 4.387
Salva come PNG Salva come JPEG
Nome #
CSF and blood biomarkers for Parkinson's disease 204
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation 160
Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis 152
Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis 141
Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis 141
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 128
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 127
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation 125
Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis 125
Visual pathway involvement in multiple sclerosis: Look straight in the eyes 117
2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes 116
Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency 112
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 110
High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease 108
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 105
Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers 105
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction 101
Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes 100
A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis 99
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease 98
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease 96
Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease 96
Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature 93
Synaptic dysfunction in multiple sclerosis: A red thread from inflammation to network disconnection 92
Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis 89
Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms 89
Molecular profiling in Parkinsonian syndromes: CSF biomarkers 86
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 86
Insights into the pathophysiology of psychiatric symptoms in central nervous system disorders: Implications for early and differential diagnosis 85
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 84
Does cerebrospinal fluid neurofilament light chain correlate with psychiatric symptoms severity in multiple sclerosis? 84
Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis 82
CSF synaptic biomarkers and cognitive impairment in multiple sclerosis 81
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 80
High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline 80
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 80
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica 79
Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain 79
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI 79
Blood biomarkers may distinguish among dementia disorders 79
The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. 78
Finding a way to preserve mitochondria: New pathogenic pathways in experimental multiple sclerosis 78
Neurofilament light chain as a biomarker in neurological disorders 77
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 76
Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use 76
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 76
Impact of post-contrast MRI in the definition of active multiple sclerosis 76
Biomarker-Based Prediction of Parkinson Disease: Time for a Shift in Neurologists' Attitude Toward Neurodegenerative Diseases 72
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion 72
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease 71
Cerebrospinal fluid interferon-γ and development of depression in multiple sclerosis 70
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective 70
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment 70
Intrathecal B cell activation and memory impairment in multiple sclerosis 69
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 69
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 69
Serum neurofilament light chain as a preclinical marker of neurodegeneration 69
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 69
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 68
Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents 68
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 68
Clinical correlates of state and trait anxiety in multiple sclerosis 65
Infliximab monotherapy for neuro-Behçet's disease: a case report 65
A blood test for Alzheimer's disease: a step forward 65
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 64
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers 63
Lower urinary tract symptoms and urodynamic dysfunctions in clinically isolated syndromes suggestive of multiple sclerosis. 62
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 60
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 60
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 59
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 59
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 59
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 56
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 54
Research advancement in fluid biomarkers for Parkinson's disease 52
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study 44
Transcriptome analysis of the prefrontal cortex identifies inflammatory genes associated with cognitive impairment in a model of multiple sclerosis 42
SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis 41
Fluid biomarkers in multiple sclerosis: from current to future applications 37
Hippocampal neuroplasticity and inflammation: Relevance for multiple sclerosis 35
Blood-based biomarkers for Alzheimer’s disease: influence of kidney function 33
Immune profiling unveils the systemic cytokine milieu associated with acute reversible encephalopathy with cytotoxic lesions of the corpus callosum (CLOCCs) 27
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders 26
Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy 21
Cerebrospinal fluid α-synuclein seed amplification assay positivity is associated with increased plasma neurofilament light chain in Alzheimer's disease 18
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease 17
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers 11
Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosis 7
Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer’s disease 2
Totale 6.888
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.524
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.524
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022377 0 49 12 12 26 10 5 93 17 46 61 46
2022/2023858 45 184 15 68 62 104 4 38 302 1 26 9
2023/2024511 24 54 15 11 7 2 97 20 68 26 80 107
2024/20251.392 13 108 69 75 122 103 95 139 239 85 220 124
2025/20263.200 205 239 128 412 430 300 503 157 298 269 160 99
2026/2027201 92 109 0 0 0 0 0 0 0 0 0 0
Totale 6.888